Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 2/20 | 0.47 |
| ▸ | TNKS | O95271 | 4/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7715490 | 0.89 | ROCK2 (0.51) | TNKSTNKS2CDC7PIM1CSNK2B | |
| SCHEMBL29499002 | 0.88 | PARP14 (0.48) | PARP14CDC7MAPK13RAF1MAPK9 | |
| SCHEMBL7714086 | 0.84 | KMT2A (0.47) | CDC7PIM1CSNK2BCSNK2A1ROCK2 | |
| SCHEMBL7715493 | 0.83 | TNKS (0.44) | PARP14TNKSTNKS2CDC7PIM1 | |
| SCHEMBL1298735 | 0.80 | PARP1 (0.49) | MAPK13RAF1MAPK9MAPK12MAPK11 | |
| SCHEMBL30496105 | 0.80 | PARP1 (0.54) | TNKSTNKS2CDC7PIM1CSNK2B | |
| SCHEMBL7713954 | 0.80 | PARP1 (0.54) | TNKSTNKS2CDC7PIM1CSNK2B | |
| Hydrochloric Acid SCHEMBL1299402 | 0.79 | PARP1 (0.48) | MAPK13RAF1MAPK9MAPK12MAPK11 | |
| Hydrochloric Acid SCHEMBL3717415 | 0.79 | PARP1 (0.48) | MAPK13RAF1MAPK9MAPK12MAPK11 | |
| Hydrochloric Acid SCHEMBL30456217 | 0.79 | PARP1 (0.48) | MAPK13RAF1MAPK9MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376500-B2 | 1-(INDOL-3-YLALKYL)ALKYLPIPERIDIN-4 -YL)-3H-QUINOLIN-4-ONE, FOR EXAMPLE; ALPHA1A/ B-RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; UROGENITAL DISORDERS; BENIGN PROSTATIC HYPERTROPHY; ANALGESICS FOR INFLAMMATORY, NEUROPATHY, CANCER, | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | CLARK ROBIN DOUGLAS (US) | 2001-12-13 | — | — | US | disclosed |
| US-6258819-B1 | BIOLOGICAL RECEPTORS, ANTIINFLAMMATORY AGENTS, BENIGN PROSTATE AND SIDE EFFECT REDUCTION | SYNTEX (U.S.A.) LLC | 2001-07-10 | — | — | US | disclosed |
| WO-2001010860-A2 | QUINAZOLINONE AND AZAQUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | ADRA2B, ADRA1D, ADRA1B | PARP14 1975/4885TNKS 1559/4885TNKS2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.